Development of neutralization antibodies against highly pathogenic H5N1 avian influenza virus using ostrich (Struthio camelus) yolk

Molecular Medicine Reports

Volumn 1, Issue 2, 2008, Pages 203-209

  Adachi, Kazuhide ^a   Handharyani, Ekowati ^c   Sari, Dwi Kesuma ^c   Takama, Kentaro ^a   Fukuda, Keiko ^a   Endo, Isako ^a   Yamamoto, Ryohei ^b   Sawa, Masaki ^b   Tanaka, Masaru ^b   Konishi, Itsuro ^b   Tsukamoto, Yasuhiro ^a  

^a Osaka Prefecture University   (Japan)

^b Ostrich Breeding Farm 'Ostrich Kobe'   (Japan)

^c BOGOR AGRICULTURAL UNIVERSITY   (Indonesia)

Author keywords

Antibody; H5N1; IgY; Influenza virus; Ostrich; Pandemic

Indexed keywords

IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; AVIAN INFLUENZA; CELL STRAIN; CHICK; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; EGG YOLK; EMBRYO; FEMALE; IMMUNOREACTIVITY; INFLUENZA VIRUS A H5N1; INOCULATION; MORTALITY; NONHUMAN; OSTRICH; PATHOGENESIS; THERAPY EFFECT; VIRUS STRAIN;

AVIAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE; STRUTHIO CAMELUS; STRUTHIONIFORMES;

EID: 69249096587     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. McCauley JW, Pullen LA, Forsyth M, Penn CR and Thomas GP: 4-Guanidino-Neu5Ac2en fails to protect chickens from infection with highly pathogenic avian influenza virus. Antiviral Res 27: 179-186, 1995.
2. Alexander DJ and Brown IH: Recent zoonoses caused by influenza A viruses. Rev Sci Tech 19: 197-225, 2000.
3. Rimmelzwaan GF and Osterhaus AD: Influenza vaccine: new developments. Curr Opin Pharmacol 1: 491-496, 2001.
4. Normile D: North Korea collaborates to fight bird flu. Science 308: 175, 2005. (Pubitemid 40558821)
5. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM and Leroux-Roels G: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic infl uenza vaccine:a randomised controlled trial. Lancet 370: 580-589, 2007. (Pubitemid 47247854)
6. Poland GA: Vaccines against avian influenza - a race against time. N Engl J Med 354: 1411-1413, 2006.
7. Sharpe M, Lynch D, Topham, Major D, Wood J and Loudon P: Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25: 6392-6398, 2007. (Pubitemid 47090232)
8. CDC: Experiences with influenza-like illness and attitude regarding influenza prevention - United States, 2003-2004 influenza season. MMWR 53: 1156-1158, 2004.
9. Schade R, Pfister C, Halatsch R and Henklein P: Polyclonal IgY antibodies from chicken egg yolkóan alternative to the production of mammalian IgG type antibodies in rabbits. ATLA 19: 403-419, 1991.
10. Schade R, Schniering A and Hlinak A: Polyclonal avian antibodies extracted from egg yolk as an alternative to the production of antibodies in mammals - a review. ALTEX 9: 43-56, 1992.
11. Gross M and Speck J: Avian yolk antibodies in diagnosis and research. Dtsch Tierarztl Wochenschr 103: 417-422, 1996.
12. Larsson A, Balow RM, Lindahl TL and Forsberg PO: Chicken antibodies: taking advantage of evolution-a review. Poult Sci 72: 1807-1812, 1993.
13. Leslie GA and Clem LW: Phylogeny of immunoglobulin structure and function. III. Immunoglobulins of the chicken. J Exp Med 130: 1337-1352, 1969.
14. Adachi K, Hagimori K, Kato H, Fukuda K, Kikuta M and Tsukamoto Y: Potential role of SC1, a cell adhesion molecule, in mammary gland tumors. Mol Med Rep (In press).
15. Reed LJ and Muench H: A simple method of estimating fifity percent end-points. Am J Hyg 27: 493-797, 1938.
16. Lu L, Yu L and Kwang J: Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. Biochem Biophys Res Commun 358: 404-409, 2007. (Pubitemid 46778910)
17. Bosch FX, Orlinch M, Klenk HD and Rott R: The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. Virology 95: 197-207, 1979. (Pubitemid 9171792)
18. Takada A, Kuboki N, Okazaki K, Ninomiya A, Tanaka H, Ozaki H, Itamura S, Nishimura H, Enami M, Tashiro M, Shortridge KF and Kida H: A virulent avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 73: 8303-8307, 1999. (Pubitemid 29441691)
19. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L, Smith DF and Nabel GJ: Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317: 825-828, 2007. (Pubitemid 47257924)
20. Kistner O, Howard OK, Spruth M, Wodal W, Bruhl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG and Barrett PN: Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036, 2007. (Pubitemid 47077543)
21. Simmons CP, Bernasconi NL, Suguitan JAL, Mills K, Ward JM, Chau NVV, Tran Tinh, Hien TT, Sallusto F, Ha DQ, Farrar J, De-Jong MD, Lanzavecchia A and Subbarao K: Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: 928-936, 2007. (Pubitemid 46842583)
22. Suarez DL and Schultz-Cherry S: Immunology of avian influenza virus: a review. Dev Comp Immunol 24: 269-283, 2000. (Pubitemid 30136306)
23. Mine Y and Kovacs-Nolan J: Chicken egg yolk antibodies as therapetutics in enteric infectious disease: a review. J Med Food 5: 159-169, 2002. (Pubitemid 35283421)
24. Carlander D, Olesen H, Kollberg H, Johannesson M, Wejaker PE and Larsson A: Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: A phase I feasibility study. Pediatr Pulmonol 35: 433-440, 2003. (Pubitemid 36629060)